CAR-T cell immunotherapy
Sponsors
Fuda Cancer Hospital, Guangzhou, First Affiliated Hospital of Chengdu Medical College, Shenzhen BinDeBio Ltd., The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, The Affiliated Hospital of Xuzhou Medical University
Conditions
B-cell Acute Lymphoblastic LeukemiaCAR-T Cell ImmunotherapyColon CancerColorectal CancerEphA2 Positive Malignant GliomaEsophageal CarcinomaEsophagus CancerGD2 Positive Glioma
Phase 1
CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients
WithdrawnNCT02575261
Start: 2015-09-30End: 2016-08-15Updated: 2020-07-16
CAR-T Cell Immunotherapy for HCC Targeting GPC3
WithdrawnNCT02723942
Start: 2015-06-30End: 2016-08-15Updated: 2020-07-16
A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer
NCT03013712
Start: 2017-01-31End: 2020-12-31Target: 60Updated: 2017-01-06
CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients
WithdrawnNCT03252171
Start: 2015-10-15End: 2016-08-15Updated: 2020-07-16
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
NCT03638206
Start: 2018-03-01End: 2023-03-01Target: 73Updated: 2019-12-11
GPC3-targeted CAR-T Cell for Treating GPC3 Positive Advanced HCC
NCT04121273
Start: 2019-10-05End: 2021-11-01Target: 20Updated: 2021-03-03
Clinical Study of CAIX-targeted CAR-T Cells in the Treatment of Advanced Renal Cell Carcinoma
RecruitingNCT04969354
Start: 2021-10-01End: 2026-09-30Target: 20Updated: 2021-07-20
Clinical Study of PSMA-targeted CAR-T Cells in the Treatment of Castration-resistant Prostate Cancer
RecruitingNCT05354375
Start: 2022-12-01End: 2026-11-30Target: 20Updated: 2022-04-29